Compare Johnson & Johnson (JNJ) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Schwab US Dividend Equity ETF — how do they compare? Johnson & Johnson trades at $261.41 (market cap $618.09B), while Schwab US Dividend Equity ETF trades at $33.03 (market cap $110.56B). The key difference: Johnson & Johnson is far larger — about 5.6× Schwab US Dividend Equity ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while Schwab US Dividend Equity ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Schwab US Dividend Equity ETF for 62 Days on average.
| JNJ | SCHD | |
|---|---|---|
Market Cap | $618.09B | $110.56B |
Volume | 6,050,983 | 23,539,168 |
Sector | Health | Broad Market / Factor |
52-Week High | $278.43 | $35.21 |
52-Week Low | $186.00 | $26.44 |
Typical Hold Time | 129 Days | 62 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
SCHD trades at $33.04, up 1.19% today, with a bullish technical signal but mixed moving averages. The ETF focuses on high-quality U.S. dividend stocks, though key valuation ratios like P/E and P/B are not provided in the data. Recent news highlights its outperformance versus the S&P 500 in 2026 and a dividend payment scheduled for September 28, 2026.
Outlook is supported by dividend growth and defensive positioning, but risks include interest rate sensitivity and strict selection rules that may exclude high-growth stocks. Analyst sentiment is mixed, with technical indicators suggesting near-term consolidation around key support at $33.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
